Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - June 2025

Why driving results from such strategies—amid industry disruption—will be critical to success.

Building Agility and Adaptability Into Pharma Operations

The advantages and challenges associated with structuring a patient assistance program as a non-profit foundation.

Changing the PAP Model

An exploration into how flawed incentives and contractual loopholes between manufacturers and pharmacy benefit managers played their part.

Popping the Gross-to-Net Bubble, Part IV: Extreme Examples of Who Grew the Bubble

Videos

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how patient and caregiver insights shape drug development, regulatory decisions, and payer considerations in rare diseases.

How Patient Advocacy Is Guiding Rare Disease Drug Development

Articles

State Medicaid leaders create a plan to ensure safety, affordability, and equitable access for children and families living with rare diseases.

Medicaid’s Role in the CGT Sector

Pharma Pulse 7/1/25: Oncology Care Index Spurs J&J to Address Fragmentation in Cancer Treatment; How Funding Cuts Are Undermining Patient Recruitment in Clinical Trials

In response to the rising importance of real-world evidence (RWE) in showing value to payers beyond traditional clinical trials, key opinion leaders emphasize finding cost-effective approaches, considering diverse patient populations, and using AI to pinpoint which patients will benefit most from treatment.

Delivering Value Beyond the Trial with Real-World Evidence

Access to the GLP-1 will be streamlined, and starting July 1, will result in a limited-time $299 price for eligible self-pay patients.

Novo Nordisk Expands Wegovy Access Through New WeightWatchers Partnership

In the fourth part of his Pharma Commerce video interview, Mark Sawicki, PhD, Cryoport Systems’ president and CEO, explains the lessons pharma leaders in traditional therapeutic areas can learn from CGT’s highly specialized operational strategies, particularly in terms of supply chain resilience and adaptability.

Leading by Example

Pharma Pulse 6/30/25: Preparing for Federal Regulations; Funding Cuts Threaten Diversity in Clinical Research

In the second part of this roundtable discussion, a panel of key opinion leaders dive into the key risk factors impacting the pharma manufacturing space, and how the industry should aim to address them.

Peer Exchange: Developing a Manufacturing Contingency Plan (Episode 2)

Dipanwita Das, CEO and co-founder of Sorcero, chats with Pharma Commerce to dig into the evolving drug development landscape, being regulatorily compliant, and the rapid advancements in artificial intelligence.

Discovering AI’s Role in Drug Safety Monitoring

Pharma Pulse 6/27/25: How AI and Machine Learning Can Improve Patient Reported Outcomes in Clinical Trials; The Role of Patient Advocacy in Shaping AbbVie's Cancer Therapies

Featured Content

Pharmaceutical Commerce - June 2025

Building Agility and Adaptability Into Pharma Operations

Changing the PAP Model

Popping the Gross-to-Net Bubble, Part IV: Extreme Examples of Who Grew the Bubble